Last reviewed · How we verify
FFI-1010
FFI-1010 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
FFI-1010 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.
At a glance
| Generic name | FFI-1010 |
|---|---|
| Sponsor | Fuji Yakuhin Co., Ltd. |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BTK is a key component of the B cell receptor signaling complex, and its inhibition has been shown to be effective in treating certain types of blood cancers. FFI-1010 works by selectively binding to and inhibiting the BTK enzyme, which can help to reduce the proliferation and survival of malignant B cells.
Approved indications
- Relapsed or refractory mantle cell lymphoma
- Relapsed or refractory marginal zone lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FFI-1010 CI brief — competitive landscape report
- FFI-1010 updates RSS · CI watch RSS
- Fuji Yakuhin Co., Ltd. portfolio CI